Navigation Links
Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy T-Cell Vaccine
Date:2/12/2010

our ongoing study in house dust mite allergy later this year," said Steve Harris, Circassia's CEO. "With three phase II studies now complete, our growing clinical database demonstrates the true potential of our ToleroMune T-cell vaccines. Unlike current immunotherapies, which require increasing doses over a number of months and several years of maintenance, ToleroMune therapy is short and simple, and minimises the risk of the severe and sometimes life-threatening side effects associated with many existing treatments."

About Circassia's allergy T-cell vaccines

Circassia's range of allergy T-cell vaccines is based on its proprietary ToleroMune(R) technology. This technology utilises allergen epitopes to generate regulatory T cells that suppress allergic immune responses. Clinical results with Circassia's cat allergy T-cell vaccine show that short treatment regimes can greatly reduce patients' symptoms, without the need for adjuvants or other immune stimulators, while proving extremely well tolerated. As a result, the company's allergy T-cell vaccines offer major potential clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is approximately $12 billion per year.

ToleroMune technology has additional potential regulatory and supply chain benefits. The short peptides utilised in Circassia's vaccines are manufactured chemically, in contrast to existing allergen immunotherapies, which are purified from natural sources. Circassia's approach applies the chemistry, manufacturing and control standards associated with conventional pharmaceuticals to its allergy T-cell vaccines. This fits with changes in the European regulatory environment, where authorities are increasin
'/>"/>

SOURCE Circassia Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Circassia Acquires North American and Japanese Rights to Dopexamine
2. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
3. Circassia Raises GBP11 Million ($21.8 Million) in Oversubscribed Second Round Funding
4. BioLife Solutions Achieves ISO 13485 Quality Management Systems Certification
5. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
6. BioNeutrals Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing.
7. BioNeutrals Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms
8. Environmental Tectonics Corporations BioMedical Division Achieves Foreign Manufacturer Accreditation in Japan
9. Healthy Advice Networks Achieves Strong Growth Despite Challenging Economy
10. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
11. Pepscan Achieves First Milestone in Research Collaboration With Genmab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... and FRANKLIN, Tenn. , ... privately-owned  premier provider of health care services and ... the U.S., today announced that its parent company ... a definitive agreement with Medical Properties Trust, Inc. ... of Capella for $900 million in cash.  The transaction is ...
(Date:7/27/2015)... ... July 27, 2015 , ... Production of high tenacity ... past few years in the EU. For instance, it surpassed the EUR 106 million ... million mark in 2010. Germany is a major producer, while Italy is a key ...
(Date:7/27/2015)... July 27, 2015 Research presented at the ... expand on the studies that led to a fingerprick ... for this disease to receive approval from the World ... breaking Ebola,s grip on West Africa ... enabling healthcare workers to isolate and treat these patients ...
(Date:7/27/2015)... July 27, 2015 The Brain ... winners of its annual Klerman and Freedman Prizes, ... who have been supported by NARSAD Young Investigator ... pursue innovative ideas in neurobiological and psychosocial research, ... for the early detection, treatment, prevention and cure ...
Breaking Biology Technology:Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6
... , , , , ... CTIC) management will present at BioCentury,s NewsMakers in the Biotech Industry conference ... The conference will be held September 16, 2009, at the ... live with slides and available for replay after the presentation. The webcast ...
... CORDOVA, Calif., Sept. 9 ThermoGenesis Corp. (Nasdaq: KOOL ... adult stem cells, today reported results for the fourth quarter and ... quarter ended June 30, 2009, the Company reported revenues of $4.0 ... quarter a year ago. As the Company indicated previously, revenues in ...
... PHILADELPHIA, Sept. 9 GlaxoSmithKline (NYSE: GSK ... (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted ... CERVARIX((R)), the company,s candidate cervical cancer vaccine (12-1 and 11-1, ... be highly effective and well tolerated in girls and young ...
Cached Biology Technology:ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 2ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 3ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 4ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 5ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 6ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 7ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 8ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 9ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 10FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKline's Candidate Cervical Cancer Vaccine 2FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKline's Candidate Cervical Cancer Vaccine 3FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKline's Candidate Cervical Cancer Vaccine 4
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. ... molecular diagnostics, today announced the launch of a ... Company,s Precision Cancer Monitoring℠ (PCM) technology for predicting ... one or a combination of the novel immunotherapy ... (nivolumab), a PD-1 inhibitor. The 50-patient study will ...
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
(Date:6/29/2015)... 2015 Research and Markets( ... "Latin America Biomedical Sensors Market - Growth, Trends & ... The Latin America Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2
... nitrogen from Arctic mushrooms to plants is shedding light ... vital nutrients to their hosts. The analytical technique, developed ... of the laboratory's Ecosystems Center and his son, Erik ... be applied to nearly all conifers, oaks, beeches, birch ...
... possible, thanks to a discovery made by a team of ... new stroke death channel ?the conduit through which key chemicals ... death that disables stroke victims. , The findings were ... an editorial in next month's issue of Nature Reviews Neuroscience. ...
... Quebec's first successful combined heart/liver transplant. The patient, Patrice ... de cardiologie de Quebec (l'hôpital Laval) to the MUHC. ... a 6-hour operation on April 14, 2006 and was ... physicians, surgeons and other health care professionals. The MUHC ...
Cached Biology News:New method confirms importance of fungi in Arctic nitrogen cycle 2UBC researchers find stroke death channel 2MUHC announces a transplant first in Quebec 2
Miniature FRENCH Pressure Cell with 3.7ml capacity; pressure up to 20,000 psi....
...
... verticillus USBio Analyzed PRODUCT SPECIFICATIONS Form: White powder Assay: 1.5 ... units/ml): 4.5 to 6.0 Loss On Drying: less than or ... 0.1% Bleomycin Content: A 2 : 55 - 70% B ... : greater than or equal to 90% B 4 : ...
... adamanteus venom Description: Phosphodiesterase I ... in studying nucleic acid structure ... hydrolyzes 5'-mononucleotides from 3'-hydroxy-terminated ribo-oligonucleotides ... I cleaves ADP-ribosylated proteins at ...
Biology Products: